Introduction
Methods
Study design
Definitions
Data analysis
Results
Baseline characteristics
Group I (Age <60 y) N = 163 | Group II (Age ≥60 ≤ 65 y) N = 122 | Group III (Age >65 y) N = 145 | |
---|---|---|---|
Age (years) | 50.4 ± 7.9 | 62.7 ± 1.8 | 68.7 ± 2.7 |
Male | 117 (71.8) | 77 (63.1) | 95 (65.5) |
EuroSCORE II | 1.2 ± 1.1 | 1.9 ± 1.9 | 2.6 ± 3.0 |
Logistic EuroSCORE | 2.5 ± 2.2 | 3.6 ± 4.2 | 5.6 ± 7.1 |
STS score (version 2.73) | 1.0 ± 0.9 | 1.5 ± 1.2 | 2.0 ± 1.7 |
Concomitant CABG | 26 (16.0) | 32 (26.2) | 48 (33.1) |
Predominant aortic stenosis | 108 (66.3) | 104 (85.2) | 120 (82.8) |
Body mass index (kg/m2) | 26 ± 3 | 26 ± 4 | 25 ± 3 |
Insulin dependent diabetes | 0 | 1 (0.8) | 5 (3.4) |
Non-insulin dependent diabetes | 5 (3.1) | 7 (5.7) | 18 (12.4) |
Paroxysmal atrial fibrillation | 9 (5.5) | 9 (7.4) | 17 (11.7) |
Permanent atrial fibrillation | 4 (2.5) | 2 (1.6) | 14 (9.7) |
Renal failure* | 3 (1.8) | 0 | 2 (1.4) |
Hypertension | 76 (46.6) | 58 (47.5) | 75 (51.7) |
History of ischaemic stroke | 6 (3.7) | 1 (0.8) | 13 (9.0) |
History of gastrointestinal bleeding | 0 | 5 (4.1) | 7 (4.8) |
Mechanical protheses
Group I (Age <60 y) N = 163 | Group II (Age ≥60 ≤ 65 y) N = 122 | Group III (Age >65 y) N = 145 | |
---|---|---|---|
Bileaflet prostheses | |||
St. Jude Medical | 79 (48.5) | 58 (47.5) | 68 (46.9) |
St. Jude Medical Hemodynamic Plus | 1 (0.6) | 1 (0.8) | 1 (0.7) |
Sorin Bicarbon | 3 (1.8) | 4 (3.3) | 4 (2.8) |
Tilting disc prostheses | |||
Sorin Allcarbon | 80 (49.1) | 59 (48.4) | 72 (49.7) |
Follow-up
Thirty-day and late mortality
Bleeding events
Group I (Age <60 y) N = 163 | Group II (Age ≥60 ≤ 65 y) N = 122 | Group III (Age >65 y) N = 145 |
P- value | |
---|---|---|---|---|
Minor bleeding | ||||
Kaplan-Meier cumulative incidence of first events (%; 95 % CI) | 45.7 (36.9–53.3) | 47.9 (36.6–57.1) | 51.3 (38.8–61.3) |
P = 0.783 |
Linearised annual incidence rate of first or recurrent events (%; 95 % CI) | 5.5 (4.6–6.5) | 6.2 (5.1–7.6) | 7.0 (5.7–8.4) |
P = 0.278 |
Major bleeding (excluding haemorrhagic stroke) | ||||
Kaplan-Meier cumulative incidence of first events (%; 95 % CI) | 29.9 (21.9–37.1) | 34.2 (23.7–43.3) | 42.7 (31.2–52.3) |
P = 0.052 |
Linearised annual incidence rate of first or recurrent events (%; 95 % CI) | 3.0 (2.4–3.7) | 4.0 (3.1–5.1) | 4.7 (3.7–5.9) |
P = 0.030* |
Haemorrhagic stroke | ||||
Kaplan-Meier cumulative incidence of first events (%; 95 % CI) | 7.6 (3.2–11.9) | 9.6 (3.3–15.6) | 7.5 (2.6–12.1) |
P = 0.947 |
Linearised annual incidence rate of first or recurrent events (%; 95 % CI) | 0.6 (0.3–1.0) | 0.7 (0.4–1.3) | 0.7 (0.3–1.2) |
P = 0.928 |